I'm thinking we must be approaching some reportable update on the September letter to share holders in regards to "conduct a preclinical TNBC study that will aim to confirm the mechanism of action of leronlimab in oncology and address the question of potential synergies with both antibody-drug conjugates and immune checkpoint inhibitors". I'm going to gander a guess that those entities that will be helping us will also be a likely partner for this indication. It's been two months since the publishing of the letter. Should be enough time to get things organized and start to move forward on implementation of the plan, I think, although I am not an expert in this and please correct me if I'm not close on the time line.

MD Anderson, your up next...